Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | INMT | O95050 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9328091 | 0.84 | GAA (0.45) | GAAL3MBTL1POLBBRD4SMN1; SMN2 | |
| SCHEMBL3123660 | 0.82 | NOTUM (0.39) | BRD4 | |
| SCHEMBL5800179 | 0.82 | GAA (0.44) | GAAL3MBTL1POLBSMN1; SMN2KDM4E | |
| SCHEMBL3224588 | 0.82 | GAA (0.44) | GAAL3MBTL1POLBBRD4SMN1; SMN2 | |
| SCHEMBL5800176 | 0.82 | GAA (0.44) | GAAL3MBTL1POLBSMN1; SMN2KDM4E | |
| SCHEMBL15632414 | 0.81 | GAA (0.46) | GAAL3MBTL1POLBSMN1; SMN2KDM4E | |
| SCHEMBL12919948 | 0.81 | GAA (0.43) | GAAL3MBTL1POLBSMN1; SMN2KDM4E | |
| SCHEMBL12566554 | 0.80 | GAA (0.48) | GAAL3MBTL1POLBSMN1; SMN2KDM4E | |
| SCHEMBL8821690 | 0.79 | GAA (0.42) | GAAL3MBTL1POLBBRD4SMN1; SMN2 | |
| SCHEMBL10772308 | 0.79 | GAA (0.45) | GAAL3MBTL1POLBSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180094139-A1 | 2,7-DISUBSTITUTED CEPHALOSPORIN DERIVATIVES AS BETA-LACTAMASE SUBSTRATES AND METHODS FOR THEIR USE FOR THE DIAGNOSIS OF TUBERCULOSIS | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2018-04-05 | — | — | US | disclosed |
| US-9834681-B2 | 2,7-disubstituted cephalosporin derivatives as beta-lactamase substrates and methods for their use for the diagnosis of tuberculosis | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170275300-A1 | SYNTHESIS OF CEPHALOSPORIN COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2017-09-28 | — | — | US | disclosed |
| US-9677112-B2 | β-lactamase substrates and methods of their use for the diagnosis of tuberculosis | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2017-06-13 | — | — | US | disclosed |
| US-20150219653-A1 | 2,7-DISUBSTITUTED CEPHALOSPORIN DERIVATIVES AS BETA-LACTAMASE SUBSTRATES AND METHODS FOR THEIR USE FOR THE DIAGNOSIS OF TUBERCULOSIS | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2015-08-06 | — | — | US | disclosed |
| US-20150167048-A1 | BETA-LACTAMASE SUBSTRATES AND METHODS OF THEIR USE FOR THE DIAGNOSIS OF TUBERCULOSIS | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2015-06-18 | — | — | US | disclosed |
| US-20150111853-A1 | CEPHALOSPORIN COMPOSITIONS AND METHODS OF MANUFACTURE | MERCK SHARP & DOHME CORP. | 2015-04-23 | — | — | US | disclosed |
| US-9006421-B2 | Cephalosporin compositions and methods of manufacture | CUBIST PHARMACEUTICALS, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| WO-2014152763-A1 | CEPHALOSPORIN COMPOSITIONS AND METHODS OF MANUFACTURE | CUBIST PHARMACEUTICALS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140274958-A1 | CEPHALOSPORIN COMPOSITIONS AND METHODS OF MANUFACTURE | MERCK SHARP & DOHME LLC | 2014-09-18 | — | — | US | disclosed |
| US-20140274999-A1 | CEPHALOSPORIN COMPOSITIONS AND METHODS OF MANUFACTURE | MERCK SHARP & DOHME CORP. | 2014-09-18 | — | — | US | disclosed |
| US-20110020240-A1 | Use of bacterial beta-lactamase for in vitro diagnostics and in vivo imaging, diagnostics and therapeutics | BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVER, THE | 2011-01-27 | — | — | US | disclosed |
| EP-1556369-A1 | PYRIDAZINONE-DERIVATIVES AS PDE4 INHIBITORS | ALTANA Pharma AG (DE) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004018451-A1 | PYRIDAZINONE-DERIVATIVES AS PDE4 INHIBITORS | ALTANA PHARMA AG (DE) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140274999-A1 | CEPHALOSPORIN COMPOSITIONS AND METHODS OF MANUFACTURE | CYP3A7, SEPTIN7, PEPD | GAA 2760/4885L3MBTL1 4302/4885POLB 2244/4885 |
| US-20140274958-A1 | CEPHALOSPORIN COMPOSITIONS AND METHODS OF MANUFACTURE | CYP3A7, SEPTIN7, PEPD | GAA 2760/4885L3MBTL1 4302/4885POLB 2244/4885 |
| US-20150111853-A1 | CEPHALOSPORIN COMPOSITIONS AND METHODS OF MANUFACTURE | CYP3A7, SEPTIN7, PEPD | GAA 2760/4885L3MBTL1 4302/4885POLB 2244/4885 |
| US-20180094139-A1 | 2,7-DISUBSTITUTED CEPHALOSPORIN DERIVATIVES AS BETA-LACTAMASE SUBSTRATES AND METHODS FOR THEIR USE FOR THE DIAGNOSIS OF TUBERCULOSIS | NAALAD2, PEPD, DCXR | GAA 82/4885L3MBTL1 1010/4885POLB 1176/4885 |
| US-20150167048-A1 | BETA-LACTAMASE SUBSTRATES AND METHODS OF THEIR USE FOR THE DIAGNOSIS OF TUBERCULOSIS | PGLS, ENGASE, BPHL | GAA 14/4885L3MBTL1 488/4885POLB 536/4885 |
| US-20150219653-A1 | 2,7-DISUBSTITUTED CEPHALOSPORIN DERIVATIVES AS BETA-LACTAMASE SUBSTRATES AND METHODS FOR THEIR USE FOR THE DIAGNOSIS OF TUBERCULOSIS | NAALAD2, PEPD, DCXR | GAA 82/4885L3MBTL1 1010/4885POLB 1176/4885 |
| US-20170275300-A1 | SYNTHESIS OF CEPHALOSPORIN COMPOUNDS | COASY, NRDC, NUCB2 | GAA 1779/4885L3MBTL1 4789/4885POLB 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.